Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903446 · ClinicalTrials.gov registry record · Phase 2
Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02903446 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT02903446, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Bone erosions are a common manifestation and feature of structural damage in severe/chronic tophaceous gout. Management of this destructive and often debilitating gout complication has focused exclusively on urate-lowering therapy (ULT) to reduce frequency of gout attacks, but little attention has been given to prevention or reversal of gout related bone erosions and other structural damage to bone caused by gout. Since there is no known effective treatment to attenuate or improve structural damage caused by gout, we propose a pilot, controlled, proof-of-concept study in which denosumab, an FDA approved medication for the treatment of bone loss, will be added to standard ULT in 20 patients with erosive gout.
Interventions
- DRUG Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2020-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903446
The ClinicalTrials.gov registry entry for NCT02903446 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Denosumab is the first listed.
NCT02903446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02903446 about?
NCT02903446 is a clinical study titled "Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions". Bone erosions are a common manifestation and feature of structural damage in severe/chronic tophaceous gout. Management of this destructive and often debilitating gout complication has focused exclusively on urate-lowering therapy (ULT) to reduce frequency of gout attacks, but little attention has b...
What is the current status of trial NCT02903446?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-02-01. Estimated completion is 2020-03-01.
What interventions are being tested in trial NCT02903446?
The interventions under investigation include: Denosumab (DRUG).
Who is sponsoring clinical trial NCT02903446?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.